Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00219180 |
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: aliskiren |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment |
Official Title: | An 8-Week Multi-Center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension |
Estimated Enrollment: | 1784 |
Study Start Date: | June 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined exclusion criteria may apply.
United States, New Jersey | |
Novartis Pharmaceuticals | |
East Hanover, New Jersey, United States, 07936 | |
Germany | |
Investigative Centers, Germany |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Study ID Numbers: | CSPP100A2327 |
Study First Received: | September 12, 2005 |
Last Updated: | November 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00219180 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hypertension, Aliskiren |
Vascular Diseases Valsartan Hypertension |
Vascular Diseases Cardiovascular Diseases Hypertension |